{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:29:05Z","timestamp":1790173745318,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["EKFK 2016-2019"],"award-info":[{"award-number":["EKFK 2016-2019"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB829"],"award-info":[{"award-number":["SFB829"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB829"],"award-info":[{"award-number":["SFB829"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Modern advances in technology such as next-generation sequencing and digital PCR make detection of minor circulating cell-free tumor DNA amounts in blood from cancer patients possible. Samples can be obtained minimal-invasively, tested for treatment-determining genetic alterations and are considered to reflect the genetic constitution of the whole tumor mass. Furthermore, tumor development can be determined by a time course of the quantified circulating cell-free tumor DNA. However, systematic studies which prove the clinical relevance of monitoring patients using liquid biopsies are still lacking. In this study, we collected 115 samples from 47 late stage melanoma patients over 1.5 years alongside therapy-associated clinical routine monitoring. Mutation status was confirmed by molecular analysis of primary tumor material. We can show that detectable levels of circulating cell-free tumor DNA correlate with clinical development over time. Increasing levels of circulating cell-free tumor DNA during melanoma treatment with either targeted therapy (BRAF\/MEK inhibitors) or immunotherapy, during recovery time or the intervals between last treatment cycle and second-line treatment point towards clinical progression before the progression becomes obvious in imaging. Therefore, this is a further possibility to closely screen our patients for tumor progression during therapy, in therapy-free phases and in earlier stages before therapy initiation.<\/jats:p>","DOI":"10.1038\/s41598-020-61818-1","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T12:46:08Z","timestamp":1584535568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients"],"prefix":"10.1038","volume":"10","author":[{"given":"Jana","family":"Knuever","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana-Diana","family":"Persa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Kreuzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Mauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Schlaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"key":"61818_CR1","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci. Transl. Med. 6, 224ra24 (2014).","journal-title":"Sci. Transl. Med."},{"key":"61818_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"J Wan","year":"2017","unstructured":"Wan, J. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer. 17, 223\u2013238 (2017).","journal-title":"Nat. Rev. Cancer."},{"key":"61818_CR3","doi-asserted-by":"publisher","first-page":"14122","DOI":"10.3390\/ijms160614122","volume":"16","author":"G Francis","year":"2015","unstructured":"Francis, G. & Stein, S. Circulating Cell-Free Tumour DNA in the Management of Cancer. Int. J. Mol. Sci. 16, 14122\u201314142 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"61818_CR4","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.18632\/oncotarget.1892","volume":"5","author":"E Shtivelman","year":"2014","unstructured":"Shtivelman, E. et al. Pathways and therapeutic targets in melanoma. Oncotarget. 5, 1701\u20131752 (2014).","journal-title":"Oncotarget."},{"key":"61818_CR5","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer, R. et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 19, 1315\u20131327 (2018).","journal-title":"Lancet Oncol."},{"key":"61818_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer, R. et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 19, 603\u2013615 (2018).","journal-title":"Lancet Oncol."},{"key":"61818_CR7","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3390\/ijms17091468","volume":"17","author":"DA Kircher","year":"2016","unstructured":"Kircher, D. A., Silvis, M. R., Cho, J. H. & Holmen, S. L. Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. Int. J. Mol. Sci. 17, 1468 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"61818_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201324 (2015).","journal-title":"N. Engl. J. Med."},{"key":"61818_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00229","author":"R V\u00e1raljai","year":"2019","unstructured":"V\u00e1raljai, R. et al. Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogenous metastatic melanoma. JCO Precision Oncology. https:\/\/doi.org\/10.1200\/PO.18.00229 (2019).","journal-title":"JCO Precision Oncology."},{"key":"61818_CR10","doi-asserted-by":"publisher","first-page":"36238","DOI":"10.18632\/oncotarget.26343","volume":"9","author":"E Long-Mira","year":"2018","unstructured":"Long-Mira, E. et al. Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. Oncotarget. 9, 36238\u201336249 (2018).","journal-title":"Oncotarget."},{"key":"61818_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.18632\/oncotarget.26451","volume":"10","author":"AC McEvoy","year":"2019","unstructured":"McEvoy, A. C. et al. Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget. 10, 113\u2013122 (2019).","journal-title":"Oncotarget."},{"key":"61818_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer."},{"key":"61818_CR13","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/nmeth.2633","volume":"10","author":"CM Hindson","year":"2013","unstructured":"Hindson, C. M. et al. Absolute Quantification by Droplet Digital PCR Versus Analog Real-Time PCR. Nat. Methods. 10, 1003\u20131005 (2013).","journal-title":"Nat. Methods."},{"issue":"1\u2013116","key":"61818_CR14","first-page":"1","volume":"11","author":"A Pflugfelder","year":"2013","unstructured":"Pflugfelder, A. et al. Malignant melanoma S3-guideline \u201cdiagnosis, therapy and follow-up of melanoma\u201d. J. Dtsch. Dermatol. Ges. 11(1\u2013116), 1\u2013126 (2013).","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"61818_CR15","doi-asserted-by":"publisher","first-page":"e24632","DOI":"10.1371\/journal.pone.0024632","volume":"6","author":"M Essler","year":"2011","unstructured":"Essler, M. et al. Prognostic value of [18F]-fluoro-deoxy-glucose PET\/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma. PLoS One. 6, e24632 (2011).","journal-title":"PLoS One."},{"key":"61818_CR16","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker, J. D. et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J. Clin. Oncol. 36, 1631\u20131641 (2018).","journal-title":"J. Clin. Oncol."},{"key":"61818_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0852-6","volume":"14","author":"M Schreuer","year":"2016","unstructured":"Schreuer, M. et al. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF\/MEK inhibitors. J. Transl. Med. 14, 95 (2016).","journal-title":"J. Transl. Med."},{"key":"61818_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3185-9","volume":"17","author":"JA Garc\u00eda-Saenz","year":"2017","unstructured":"Garc\u00eda-Saenz, J. A. et al. Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. BMC Cancer. 17, 210 (2017).","journal-title":"BMC Cancer."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61818-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61818-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61818-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T08:04:20Z","timestamp":1670313860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61818-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["61818"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-61818-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,18]]},"assertion":[{"value":"10 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4940"}}